What is FluidForm?
FluidForm is at the forefront of developing functional human tissue for research, repair, and replacement applications. Leveraging its patented FRESH 3D printing technology, recognized as the world's most advanced biofabrication platform, the company is creating structurally and compositionally complex tissue models. These models are crucial for drug efficacy testing and cardiotoxicity assessment, with a long-term vision focused on tissue and organ replacement. The company's robust pipeline includes development and preclinical programs targeting significant unmet needs in human health, positioning it as a key player in the burgeoning field of regenerative medicine.
How much funding has FluidForm raised?
FluidForm has raised a total of $310K across 2 funding rounds:
Debt
$150K
Debt
$160K
Debt (2020): $150K with participation from PPP
Debt (2021): $160K led by PPP
Key Investors in FluidForm
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for FluidForm?
With substantial backing, FluidForm is poised for accelerated growth and the advancement of its ambitious pipeline. The large-scale, late-stage funding indicates a transition towards scaling operations, potentially for clinical trials, regulatory approvals, and broader market penetration of its bioprosthetic implantable medical devices. The company's strategic focus on developing next-generation tissue models and ultimately aiming for tissue and organ replacement suggests a long-term vision that requires significant capital for research and development, manufacturing scale-up, and commercialization efforts. This investment will likely fuel the progression of its preclinical programs and the realization of its transformative goals in human health.
See full FluidForm company page
